An engineered human follistatin variant: Insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 3, 2013, Pages 616-623

  Datta Mannan, Amita ^a   Yaden, Benjamin ^c,d   Krishnan, Venkatesh ^c,d   Jones, Bryan E ^b   Croy, Johnny E ^b  

^a Departments of Drug Disposition Development/Commercialization   (United States)

^b Applied Molecular Evolution   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Indiana University Purdue University Indianapolis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLISTATIN; FOLLISTATIN 315; HEPARAN SULFATE; IMMUNOGLOBULIN G1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MOUSE; MUSCLE ATROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN INTERACTION; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLISTATIN; HALF-LIFE; HEK293 CELLS; HEPARIN; HUMANS; IMMUNOGLOBULIN G; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MUSCULAR ATROPHY; PROTEIN BINDING; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SEPHAROSE;

EID: 84874427632     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.201491     Document Type: Article

References (37)

1. Abe Y, Abe T, Aida Y, Hara Y, and Maeda K (2004) Follistatin restricts bone morphogenetic protein (BMP)-2 action on the differentiation of osteoblasts in fetal rat mandibular cells. J Bone Miner Res 19:1302-1307.
2. Amthor H, Christ B, Rashid-Doubell F, Kemp CF, Lang E, and Patel K (2002) Follistatin regulates bone morphogenetic protein-7 (BMP-7) activity to stimulate embryonic muscle growth. Dev Biol 243:115-127.
3. Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, and Patel K (2004) Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Dev Biol 270:19-30.
4. Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, and Zako M (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777.
5. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, and Wroblewski VJ (2007) Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: Relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 35:86-94.
6. de Kretser DM, O'Hehir RE, Hardy CL, and Hedger MP (2012) The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol Cell Endocrinol 359:101-106.
7. Dordal MS, Wang FF, and Goldwasser E (1985) The role of carbohydrate in erythropoietin action. Endocrinology 116:2293-2299.
8. Fainsod A, Deissler K, Yelin R, Marom K, Epstein M, Pillemer G, Steinbeisser H, and Blum M (1997) The dorsalizing and neural inducing gene follistatin is an antagonist of BMP-4. Mech Dev 63:39-50.
9. Foley JW, Bercury SD, Finn P, Cheng SH, Scheule RK, and Ziegler RJ (2010) Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice. Mol Ther 18:1584-1591.
10. Fukuda MN, Sasaki H, Lopez L, and Fukuda M (1989) Survival of recombinant erythropoietin in the circulation: The role of carbohydrates. Blood 73:84-89.
11. Fumagalli M, Musso T, Vermi W, Scutera S, Daniele R, Alotto D, Cambieri I, Ostorero A, Gentili F, and Caposio P, et al. (2007) Imbalance between activin A and follistatin drives postburn hypertrophic scar formation in human skin. Exp Dermatol 16:600-610.
12. Fuwii M, Ishikawa M, Iuchi M, and Tashiro S (2005) Effect of follistatin on rat liver regeneration and tumor growth after portal occlusion. Hepatogastroenterology 52: 833-838.
13. Goebl NA, Babbey CM, Datta-Mannan A, Witcher DR, Wroblewski VJ, and Dunn KW (2008) Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell 19:5490-5505.
14. Hyuga M, Itoh S, Kawasaki N, Ohta M, Ishii A, Hyuga S, and Hayakawa T (2004) Analysis of site-specific glycosylation in recombinant human follistatin expressed in Chinese hamster ovary cells. Biologicals 32:70-77.
15. Iemura S-I, Yamamoto TS, Takagi C, Uchiyama H, Natsume T, Shimasaki S, Sugino H, and Ueno N (1998) Direct binding of follistatin to a complex of bonemorphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci USA 95:9337-9342.
16. Inouye S, Ling N, and Shimasaki S (1992) Localization of the heparin binding site of follistatin. Mol Cell Endocrinol 90:1-6.
17. Keutmann HT, Schneyer AL, and Sidis Y (2004) The role of follistatin domains in follistatin biological action. Mol Endocrinol 18:228-240.
18. Kogure K, Omata W, Kanzaki M, Zhang YQ, Yasuda H, Mine T, and Kojima I (1995) A single intraportal administration of follistatin accelerates liver regeneration in partially hepatectomized rats. Gastroenterology 108:1136-1142.
19. Kogure K, Zhang YQ, Kanzaki M, Omata W, Mine T, and Kojima I (1996) Intravenous administration of follistatin: Delivery to the liver and effect on liver regeneration after partial hepatectomy. Hepatology 24:361-366.
20. Kota J, Handy CR, Haidet AM, Montgomery CL, Eagle A, Rodino-Klapac LR, Tucker D, Shilling CJ, Therlfall WR, and Walker CM, et al. (2009) Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med 1: Ra15.
21. Kuo TT and Aveson VG (2011) Neonatal Fc receptor and IgG-based therapeutics. MAbs 3:422-430.
22. Medina J, Yamada S, and Kojima I (2009) Identification of differentially expressed genes during proliferative response of the liver induced by follistatin. Endocr J 56: 1067-1077.
23. Otsuka F, Moore RK, Iemura S, Ueno N, and Shimasaki S (2001) Follistatin inhibits the function of the oocyte-derived factor BMP-15. Biochem Biophys Res Commun 289:961-966.
24. Phillips DJ and de Kretser DM (1998) Follistatin: A multifunctional regulatory protein. Front Neuroendocrinol 19:287-322.
25. Piltonen M, Bespalov MM, Ervasti D, Matilainen T, Sidorova YA, Rauvala H, Saarma M, and Männistö PT (2009) Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp Neurol 219:499-506.
26. Schneyer AL, Sidis Y, Gulati A, Sun JL, Keutmann HT, and Krasney PA (2008) Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology 149:4589-4595.
27. Sharma M, Langley B, Bass J, and Kambadur R (2001) Myostatin in muscle growth and repair. Exerc Sport Sci Rev 29:155-158.
28. Sidis Y, Schneyer AL, and Keutmann HT (2005) Heparin and activin-binding determinants in follistatin and FSTL3. Endocrinology 146:130-136.
29. Sidis YM, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, and Schneyer A (2006) Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology 147:3586-3597.
30. Takabe K, Wang L, Leal AM, Macconell LA, Wiater E, Tomiya T, Ohno A, Verma IM, and Vale W (2003) Adenovirus-mediated overexpression of follistatin enlarges intact liver of adult rats. Hepatology 38:1107-1115.
31. Tsuchida K (2008) Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice. Acta Myol 27:14-18.
32. Tsuda E, Kawanishi G, Ueda M, Masuda S, and Sasaki R (1990) The role of carbohydrate in recombinant human erythropoietin. Eur J Biochem 188:405-411.
33. Vugmeyster Y, Xu X, Theil FP, Khawli LA, and Leach MW (2012) Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem 3:73-92.
34. Wankell M, Munz B, Hübner G, Hans W, Wolf E, Goppelt A, and Werner S (2001) Impaired wound healing in transgenic mice overexpressing the activin antagonist follistatin in the epidermis. EMBO J 20:5361-5372.
35. Weiss P and Ashwell G (1989) The asialoglycoprotein receptor: Properties and modulation by ligand. Prog Clin Biol Res 300:169-184.
36. Zhang F, Beaudet JM, Leudeke DM, Walker RG, Thompson TB, and Linhardt RJ (2012) Analysis of the interaction between heparin and follistatin and heparin and follistatin-ligand complexes using surface plasmon resonance. Biochemistry 51: 6791-6803.
37. Zimber MP, Ziering C, Zeigler F, Hubka M, Mansbridge JN, Baumgartner M, Hubka K, Kellar R, Perez-Meza D, and Sadick N, et al. (2011) Hair regrowth following a Wnt-and follistatin containing treatment: Safety and efficacy in a first-in-man phase 1 clinical trial. J Drugs Dermatol 10:1308-1312.